Extract

The purpose of this study is to compare the safety, tolerability and antiviral activity between once-daily (QD) and twice-daily (BID) dosing of lopinavir/ritonavir and to further characterize the pharmacokinetics of once-daily dosing of lopinavir/ritonavir.

Inclusion criteria

• HIV Infections

Country

• Australia
• France
• Germany
• Singapore
• Spain
• United Kingdom
• United States

Links

• ictrp
• nct